dipyridamole has been researched along with Cardiac Death in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ziadi, MC | 1 |
| Dekemp, RA | 1 |
| Williams, KA | 1 |
| Guo, A | 1 |
| Chow, BJ | 1 |
| Renaud, JM | 1 |
| Ruddy, TD | 1 |
| Sarveswaran, N | 1 |
| Tee, RE | 1 |
| Beanlands, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ammonia N-13 Myocardial Blood Flow Absolute Quantification by Positron Emission Tomography in Patients With Known or Suspected Coronary Artery Disease (Ammonia MAP)[NCT04343209] | 2,500 participants (Anticipated) | Observational | 2020-09-14 | Recruiting | |||
| Prospective Evaluation of Chemotherapy-Induced Cardiotoxicity by Serial PET Myocardial Perfusion and Blood Flow Assessment - the PRECISION Trial[NCT05913999] | 60 participants (Anticipated) | Observational | 2023-06-01 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for dipyridamole and Cardiac Death
| Article | Year |
|---|---|
Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia.
Topics: Aged; Death; Dipyridamole; Electrocardiography; Exercise Test; Female; Fractional Flow Reserve, Myoc | 2011 |
Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia.
Topics: Aged; Death; Dipyridamole; Electrocardiography; Exercise Test; Female; Fractional Flow Reserve, Myoc | 2011 |
Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia.
Topics: Aged; Death; Dipyridamole; Electrocardiography; Exercise Test; Female; Fractional Flow Reserve, Myoc | 2011 |
Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia.
Topics: Aged; Death; Dipyridamole; Electrocardiography; Exercise Test; Female; Fractional Flow Reserve, Myoc | 2011 |